Bio-PARK

The construction of Yaoming Biological Life Science Park started

The construction of Yaoming Biological Life Science Park started

(Summary description)Wuxi Daily Wuxi Observation Wuxi New Media

Wuxi WuXi PharmaTech Biotechnology Co., Ltd., which was registered in Wuxi eight years ago, announced today that the first phase of the Yaoming Biological Life Science and Technology Park in Mashan was officially launched.

Information

Wuxi Daily Wuxi Observation Wuxi New Media

Wuxi WuXi PharmaTech Biotechnology Co., Ltd., which was registered in Wuxi eight years ago, announced today that the first phase of the Yaoming Biological Life Science and Technology Park in Mashan was officially launched.

new

new

The total area of Yaoming Biological Life Science and Technology Park is about 400 mu, and the first phase covers an area of 70 mu. The Life Science and Technology Park will combine the R&D and production areas, build commercial training centers and biomedical localization equipment centers, and build the global headquarters of PharmaTech, which is the world's largest biomedical research and development, production, training, international cooperation and exchange, and business support. One of the integration centers for biopharmaceutical research, development and production.

new
 

In the past eight years, Yaoming Bio has created an important milestone in China's biopharmaceutical industry. As early as 2012, Wuming Biology built China's first world-leading biopharmaceutical production base in Wuxi that meets US, EU and Chinese cGMP standards, and gradually increased its production capacity to 6,000 liters. In December 2017, Yaoming Biotech fully commissioned a biopharmaceutical cGMP production base with a total capacity of 30,000 liters and the world's largest disposable reactor.

new

In August 2017, the US FDA completed the PLI examination of the drug-based cGMP stock solution and the sterile preparation base. In March of this year, Yaoming Bio was the long-acting innovative biological drug (mAb) produced by Zhongyu New Drug, Trogarzo in March of this year. Approved by the US FDA, it has become the world's top ten FDA-certified biopharmaceutical R&D platform companies, and has become the only biopharmaceutical company in China that has passed the US FDA GMP certification.

new

Up to now, the innovative biopharmaceuticals produced by PharmaTech have been approved for clinical trials in more than a dozen countries and regions including the United States, Canada, Europe, Australia, Singapore and South Korea.

“Investing in the construction of Wuming Biological Life Science and Technology Park is another important milestone in the development of Yaoming Biological.” Dr. Chen Zhisheng, CEO of Yaoming Bio, said that this investment will further consolidate the discovery, development and production of Wuming Biological in biomedicine. Service capabilities.

After completion, the Pharmacy Biotechnology Park will serve customers at home and abroad with a comprehensive one-stop service cooperation model and the highest quality standards, and will reduce the innovation and entrepreneurial threshold in biomedicine and health in a new way. Innovative entrepreneurs in related fields provide integrated services, become an incubation base for biomedical innovation and entrepreneurship, a talent training base, an international cooperation exchange base and an international gathering place for innovative talents, accelerate global biopharmaceutical research and development, promote the development of China's pharmaceutical health industry, and benefit the disease. Suffering. (Reporter Yin Hui)